palfreymanbiopharm.com
Clients
http://www.palfreymanbiopharm.com/clients.html
Since its inception, Palfreyman BioPharm Advisors has worked with a wide range of companies. Over the years, these have included:. Actea Ventures, GmbH. Aminex Therapeutics, Inc. Amorsa Therapeutics, Inc. Amakem Therapeutics, NV. Chemical Diversity, Inc. EnVivo (Forum) Pharmaceuticals, Inc. Jasco Pharmaceuticals, Inc. Neuron Systems, Inc. (now Aldeyra Therapeutics, Inc. Marc Pharmaceuticals, Inc. SK Life Sciences, Inc. Thrasos Therapeutics, Inc. Torrey Pines Investment, Inc.
ceo-roundtable.com
::- CEO Roundtable -::
http://www.ceo-roundtable.com/websites1.asp
Follow us on Twitter. Join us on LinkedIn. Loren G. Carlson Bio. Who Joins CEO Roundtable. Members in the News. Links to Members' Websites. The peers in my CEO Roundtable group are my trusted advisors. CEO, Ascent Therapeutics. I have been a member of the CEO Roundtable for seven years. During that time I have met . CEO, Odyssey Bay Ventures, Inc. Sign up to receive CEO Roundtable. Steven G. Cecil. 160; Company Name. 160; Website Address. Atlantic Consultants, Inc. Boston Neurofeedback Ctr., PC.
beantownweb.blogspot.com
Beantown Web: Startup Watch | January 2011
http://beantownweb.blogspot.com/2011/02/startup-watch-january-2011.html
The mission of Beantown Web is to provide information about Web Development training and career opportunities in the greater Boston area. Sunday, February 27, 2011. Startup Watch January 2011. As the job market for Web technology professionals heats up, the market for ninjas. Founder and CTO at HubSpot, is looking for developers. There is just one catch. Only awesome. This is not just a Boston phenomenon. Rand Fishkin. To be considered you must be amazing. Yes, if you can demonstrate GRANA skills:. For d...
sitran.org
Accelerating the development of treatments for Charcot-Marie-Tooth Disease - SITraN
http://www.sitran.org/news/charcot-marie-tooth-collaboration
Accelerating the development of treatments for Charcot-Marie-Tooth Disease. Dr Grierson said The zebrafish model offers a unique opportunity for preclinical testing in CMT2A, the most common form of axonal CMT. With support from HNF we have refined and validated this model. Through this new partnership we will discover whether HDAC6 inhibition is a viable therapeutic approach . For further information, visit www.hnf-cure.org. Faculty of Medicine, Dentistry and Health.
bertonlab.com
BERTON LAB - What's new
http://www.bertonlab.com/whats-new.html
New paper online at Biological Psychiatry. New paper by Jeanine Jochems entitled " Enhancement of stress resilience through Hdac6-mediated regulation of glucocorticoid receptor chaperone dynamics" just came out online . The paper describes a new molecular mechanism key for stress resilience and zero-in on a potential molecular target for future treatments. The study characterized the role of Hsp90 de-acetylation by HDAC6 in Glucocorticoid Receptor responses to stress hormones and Stress resilience.
collaborativedrug.com
CDD Vault Case Studies | CDD - Drug Discovery Informatics on the web
https://www.collaborativedrug.com/pages/case_studies
Start your free trial. CDD Vault Case Studies. The FP7-funded Kinetoplastid Drug Development (KINDReD) consortium has been created to strengthen and advance the current drug development pipeline in neglected infectious diseases. The consortium’s key objective is to bring promising anti-trypanosomatid drug discovery initiatives forward by combining the strengths of key experts in industry and academia to create a unique and powerful drug discovery platform with the common goal of advancing promi...The NIH...
researchoncology.com
Scientific Platforms & Pipeline: Thematic Centers of Excellence - Epigenetics | Celgene Clinical Research
http://www.researchoncology.com/platforms-and-pipeline/centers-of-excellence/epigenetics
Scientific Platforms & Pipeline. Thematic Centers of Excellence. Scientific Platforms & Pipeline. Scientific Platforms & Pipeline. Thematic Centers of Excellence. Thematic Centers of Excellence. Thematic Centers of Excellence. To optimize the viewing experience of this page, please turn phone to landscape orientation. Hypomethylating Agents (HMAs) With Immuno-Oncology Agents. Chemotherapy With Immuno-Oncology Agents. Chimeric Antigen Receptor Technology (CAR-T). Isocitrate Dehydrogenase (IDH) Mutations.
